Biotech firm raises £40m for R&D
AIM-listed biotech firm e-Therapeutics placed £40m of new shares with institutional investors in a deal that will fund R&D spending over the next four years.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts